Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
NCT03984448Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2019
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), sponsored by National Cancer Institute. Started Oct 2019; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT03984448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03984448.